Related references
Note: Only part of the references are listed.New Peptide Vaccine for HER2-Expressing Breast Tumors
Sue Rochman
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
New Peptide Vaccine for HER2-Expressing Breast Tumors
Sue Rochman
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer
Sheida Shariat et al.
CANCER LETTERS (2014)
The nanoparticulation by octaarginine-modified liposome improves α-galactosylceramide-mediated antitumor therapy via systemic administration
Takashi Nakamura et al.
JOURNAL OF CONTROLLED RELEASE (2013)
Liposomes containing monophosphoryl lipid A: A potent adjuvant system for inducing antibodies to heroin hapten analogs
Gary R. Matyas et al.
VACCINE (2013)
GM-CSF enhances tumor invasion by elevated MMP-2,-9, and-26 expression
Claudia M. Gutschalk et al.
CANCER MEDICINE (2013)
Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines
Carl R. Alving et al.
EXPERT REVIEW OF VACCINES (2012)
Synchronization of Dendritic Cell Activation and Antigen Exposure Is Required for the Induction of Th1/Th17 Responses
Arun T. Kamath et al.
JOURNAL OF IMMUNOLOGY (2012)
The GP2 peptide: A HER2/neu-based breast cancer vaccine
Kevin S. Clive et al.
JOURNAL OF SURGICAL ONCOLOGY (2012)
Phase I study of a Neisseria meningitidis liposomal vaccine containing purified outer membrane proteins and detoxified lipooligosaccharide
Wendell D. Zollinger et al.
VACCINE (2012)
Use of defined TLR ligands as adjuvants within human vaccines
Malcolm S. Duthie et al.
IMMUNOLOGICAL REVIEWS (2011)
Nanoparticle Delivery Systems in Cancer Vaccines
Yogita Krishnamachari et al.
PHARMACEUTICAL RESEARCH (2011)
Effect of vesicle size on tissue localization and immunogenicity of liposomal DNA vaccines
Myrra G. Carstens et al.
VACCINE (2011)
Results of the First Phase 1 Clinical Trial of the HER-2/neu Peptide (GP2) Vaccine in Disease-Free Breast Cancer Patients
Mark G. Carmichael et al.
CANCER (2010)
A novel liposomal vaccine improves humoral immunity and prevents tumor pulmonary metastasis in mice
Zhenghua Zhong et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2010)
Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12
Antonella Rigo et al.
MOLECULAR CANCER (2010)
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
Martin F. Bachmann et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Disterolphospholipids: Nonexchangeable Lipids and Their Application to Liposomal Drug Delivery
Zhaohua Huang et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2009)
Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine
Weihsu Chen et al.
MOLECULAR PHARMACEUTICS (2008)
Engagement of TLR signaling as adjuvant: Towards smarter vaccine and beyond
Amit Lahiri et al.
VACCINE (2008)
Optimizing dosage of ketamine and xylazine in murine echocardiography
Qi Xu et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2007)
Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo
Claudia M. Gutschalk et al.
CANCER RESEARCH (2006)
Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer
Elizabeth A. Mittendorf et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial
Elizabeth A. Mittendorf et al.
CANCER (2006)
Immunostimulatory colloidal delivery systems for cancer vaccines
Anne Saupe et al.
EXPERT OPINION ON DRUG DELIVERY (2006)
Immunogenic HER-2/neu peptides as tumor vaccines
CN Baxevanis et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct
A Roth et al.
BRITISH JOURNAL OF CANCER (2005)
Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Fp-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor
J Neidhart et al.
VACCINE (2004)
Cancer immunotherapy: moving beyond current vaccines
SA Rosenberg et al.
NATURE MEDICINE (2004)
Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer
EC Dees et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
Enhanced adjuvantic property of polymerized liposome as compared to a phospholipid liposome
JM Jeong et al.
JOURNAL OF BIOTECHNOLOGY (2002)
Liposomal delivery of CTL epitopes to dendritic cells
G Chikh et al.
BIOSCIENCE REPORTS (2002)
Cancer vaccines and immunotherapy
S Dermime et al.
BRITISH MEDICAL BULLETIN (2002)
Efficient delivery of antennapedia homeodomain fused to CTL epitope with liposomes into dendritic cells results in the activation of CD8+ T cells
GG Chikh et al.
JOURNAL OF IMMUNOLOGY (2001)
Modification of the HER2/neu-derived tumor antigen GP2 improves induction of GP2-reactive cytotoxic T lymphocytes
Y Tanaka et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Update on HER-2 as a target for cancer therapy - HER2/neu peptides as tumour vaccines for T cell recognition
I Correa et al.
BREAST CANCER RESEARCH (2001)
In vivo antigen loading and activation of dendritic cells via a liposomal peptide vaccine mediates protective antiviral and anti-tumour immunity
B Ludewig et al.
VACCINE (2000)
Share Paper
